Insider Selling: Liquidia (NASDAQ:LQDA) Insider Sells 18,314 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) insider Scott Moomaw sold 18,314 shares of Liquidia stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $36.79, for a total transaction of $673,772.06. Following the sale, the insider owned 187,640 shares in the company, valued at $6,903,275.60. This represents a 8.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Scott Moomaw also recently made the following trade(s):

• On Monday, January 12th, Scott Moomaw sold 20,533 shares of Liquidia stock. The stock was sold at an average price of $37.43, for a total transaction of $768,550.19.

Liquidia Stock Up 4.0%

Shares of LQDA stock traded up $1.41 on Wednesday, hitting $36.61. The stock had a trading volume of 1,015,932 shares, compared to its average volume of 1,932,669. The stock’s 50 day moving average is $37.81 and its 200-day moving average is $31.70. The firm has a market capitalization of $3.23 billion, a price-to-earnings ratio of -44.11 and a beta of 0.52. Liquidia Corporation has a 52-week low of $11.26 and a 52-week high of $46.67. The company has a debt-to-equity ratio of 2.97, a quick ratio of 1.84 and a current ratio of 2.01.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Thursday, March 5th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.07. Liquidia had a negative net margin of 43.53% and a negative return on equity of 209.33%. The firm had revenue of $92.02 million for the quarter, compared to the consensus estimate of $87.49 million. The company’s revenue for the quarter was up 3072.4% compared to the same quarter last year. As a group, research analysts expect that Liquidia Corporation will post -1.51 earnings per share for the current year.

Analyst Ratings Changes

LQDA has been the topic of several recent analyst reports. Wall Street Zen upgraded Liquidia from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Lifesci Capital upgraded Liquidia to a “strong-buy” rating in a research note on Thursday, March 5th. Raymond James Financial restated a “strong-buy” rating on shares of Liquidia in a report on Thursday, March 5th. Oppenheimer increased their target price on Liquidia from $16.00 to $19.00 and gave the company an “underperform” rating in a research note on Thursday, March 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $43.44.

Institutional Trading of Liquidia

Several hedge funds and other institutional investors have recently bought and sold shares of LQDA. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Liquidia in the 4th quarter valued at approximately $25,000. NewEdge Advisors LLC acquired a new position in Liquidia during the 2nd quarter valued at approximately $25,000. Skandinaviska Enskilda Banken AB publ bought a new position in Liquidia during the 3rd quarter worth $30,000. FNY Investment Advisers LLC acquired a new stake in Liquidia in the third quarter worth $34,000. Finally, Covestor Ltd increased its holdings in shares of Liquidia by 41.9% in the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after acquiring an additional 359 shares during the period. 64.54% of the stock is owned by institutional investors.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).